NCT00622908已完成2 期
A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 270
- 主要终点
- Clinical Resolution of Baseline Bacterial Conjunctivitis (Day 8 or 9)
研究概览
简要总结
To evaluate the clinical and microbial efficacy of ISV-403 administered three times a day (TID) for 5 days compared to vehicle three times a day for 5 days in the treatment of bacterial conjunctivitis
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 1 Year 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must be at least one year of age.
- •Must have signature of subject or legally authorized representative (if subject is under 18 years of age) on the informed Consent Form.
- •Must have signature of subject on the Assent Form if subject is 6 to 17 years of age.
- •Must have a clinical diagnosis of acute bacterial conjunctivitis and exhibit purulent conjunctival discharge (crusty or sticky eyelids) and redness in at least one eye. A minimum score of 1 should be present for discharge and a minimum score of 1 for either bulbar or palpebral conjunctival injection.
- •Must have pinholed visual acuity equal to or better than 20/200 in both eyes. Age appropriate visual acuity testing was to be performed. Every effort was made to obtain a visual acuity measurement in children. If visual acuity was unobtainable in children, it was at the investigator's discretion to meet inclusion criteria.
- •Must be willing to discontinue contact lens wear for the duration of the study.
- •Must be willing to avoid disallowed medications during the study period.
- •Must understand the scope of the study including completion of diary, be willing to follow instructions, and be able to make all required study visits.
- •If a subject was a female of childbearing potential, she must utilize reliable contraceptive methods and have a negative pregnancy test.
排除标准
- •Any uncontrolled systemic disease or debilitating disease.
- •Use of topical ophthalmic solutions including tear substitutes within two hours before and during the study.
- •Use of any ophthalmic topical anti-inflammatory agents within 48 hours before and during the study.
- •Subjects likely to require antimicrobial therapy with any active respiratory tract infection, urinary tract infection, skin/soft tissue infection, or otitis media.
- •Pregnant or nursing females.
- •Known hypersensitivity to SS734 or to any of the ingredients in the study medications.
- •Known hypersensitivity to fluoroquinolones or to any of the ingredients in the study medications.
- •Ocular surgery (including laser surgery) in either eye within the past six weeks.
- •Subjects with suspected viral or allergic conjunctivitis (i.e., severe itching or acute follicular conjunctivitis), or any other disease conditions that could interfere with the efficacy and safety evaluations of the study medication.
- •Subjects with suspected iritis (i.e., smaller pupil, pain, and photophobia in infected eye).
- •History of recurrent corneal erosion syndrome, either idiopathic or secondary to previous corneal trauma or dry eye syndrome.
- •Use of any antibiotic within 72 hours of enrollment.
- •Any active ulcerative keratitis, specifically any epithelial loss greater than punctate keratitis
- •Participation in an ophthalmic drug or device research study within the 30 days prior to entry in this study.
- •Subjects who were immune compromised.
研究组 & 干预措施
ISV-403
Experimental
ISV-403 0.6%
干预措施: ISV-403 (Drug)
Vehicle
Placebo Comparator
Vehicle of ISV-403
干预措施: Vehicle (Drug)
结局指标
主要结局
Clinical Resolution of Baseline Bacterial Conjunctivitis (Day 8 or 9)
时间窗: Visit 3 - day 8 or 9
Resolution of conjunctival discharge, bulbar conjunctival injection and palpebral conjunctival injection.
Eradication of Baseline Pathogens (Day 8 or 9)
时间窗: Visit 3 - Day 8 or day 9
Bacterial species eradication of baseline bacterial infection
次要结局
- Clinical Resolution of Baseline Bacterial Conjunctivitis Day 4 (+/- 1 Day)(Visit 2 - Day 4 (+/- 1 day))
- Eradication of Baseline Pathogens Day 4 (+/- 1 Day)(Visit 2 - Day 4 (+/- 1 day))
研究者
相似试验
已完成
3 期
A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.Acute Bacterial ConjunctivitisNCT00347932Bausch & Lomb Incorporated957
已完成
2 期
Study of Efficacy of Levofloxacin 0.5% Ophthalmic Solution Administered Three Times a Day for Bacterial ConjunctivitisBacterial ConjunctivitisNCT00565123Laser Microsurgery Centre, Poland119
已完成
3 期
IS-001 Injection in Patients Undergoing Robotic-Assisted Gynecological SurgeryUreter InjuryNCT05954767Intuitive Surgical189
已完成
2 期
Safety and Efficacy of 333369 in the Treatment of Partial EpilepsyRefractory EpilepsyNCT00228969SK Life Science, Inc.
已完成
3 期
A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101)NCT06585696Cutia Therapeutics（Wuxi）Co.,Ltd554